EpiVax is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company.

EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998  EpiVax Founded by Dr. Annie De Groot and Mr. Bill Martin Following years of training in internal medicine, immunology, immunoinformatics, and vaccinology, ...

PROVIDENCE, RI, January 10, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2. The new tool provides a quick turnaround, powerful way to provide near real-time ...

EpiVax, Inc. is excited to announce that its subsidiary, EpiVax Therapeutics, has signed an exclusive collaboration agreement with GreenLight Biosciences to advance the development of personalized cancer vaccines.   The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of ...

“I have found that among its other benefits, giving liberates the soul of the giver.” – Maya Angelou EpiVax’s VaxGivesBack Fund kicked the holiday off by partnering with AIDS Care Ocean State  and Clinica Esperanza/Hope Clinic to distribute gifts to local families. Pictures of the gift giveaway at CEHC last weekend are linked here. This is the 4th ...

EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine PROVIDENCE, RI, October 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope ...

PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for improving biosimilar product development and assessing product ...

PROVIDENCE, RI, June 10, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R43AI058376). The company is looking for a strategic partner with funding ...

PROVIDENCE, RI, May 25, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity” in Frontiers in Immunology, a collaboration with Massachusetts General Hospital’s (“MGH”) Vaccine and Immunotherapy Center, the Oxford Vaccine Group, Colorado State University, and Innatoss ...

PROVIDENCE, RI, February 8, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the establishment of the Vax Gives Back Fund at the Rhode Island Foundation, a step to continue the strong tradition of corporate responsibility and community service at the company. EpiVax has a long standing commitment to charitable giving since the company’s inception in 1998. Dr. ...

PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. (“EVT”) are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022. EPV-CoV-19, is intended for ...

PROVIDENCE, RI, November 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication of three papers focusing on malaria vaccine efficacy, part of a collaboration with Leidos, the University of Georgia Center for Vaccines and Immunology, the University of Oxford’s Jenner Institute, and Sanofi Pasteur’s VaxDesign Campus.  The work was supported by the Office of Infectious ...

EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenberg’s work has focused on immune tolerance induction and immunogenicity. ...

PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies peptide epitopes associated with T cell immunity to SARS-CoV-2 and confirms that recovering patients produce a memory immune response to iVAX-predicted ...